DARK Classics in Chemical Neuroscience: Psilocybin

Psilocybin is found in a family of mushrooms commonly known as “magic mushrooms” that have been used throughout history to induce hallucinations. In the late 1950s Albert Hofmann, of Sandoz Laboratories, identified and synthesized the psychoactive compounds psilocybin and psilocin which are found in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:ACS chemical neuroscience 2018-10, Vol.9 (10), p.2438-2447
Hauptverfasser: Geiger, Haden A, Wurst, Madeline G, Daniels, R. Nathan
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2447
container_issue 10
container_start_page 2438
container_title ACS chemical neuroscience
container_volume 9
creator Geiger, Haden A
Wurst, Madeline G
Daniels, R. Nathan
description Psilocybin is found in a family of mushrooms commonly known as “magic mushrooms” that have been used throughout history to induce hallucinations. In the late 1950s Albert Hofmann, of Sandoz Laboratories, identified and synthesized the psychoactive compounds psilocybin and psilocin which are found in psilocybe mushrooms. Psilocybin was marketed by Sandoz as Indocybin for basic psychopharmacological and therapeutic clinical research. Psilocybin saw a rapid rise in popularity during the 1960s and was classed as a Schedule I drug in 1970. This led to a significant decrease in psilocybin research. Recently, however, preliminary studies with psilocybin have shown promise as potential for the treatment of obsessive compulsive disorder, alcohol addiction, tobacco addiction, and major depressive disorder, and the treatment of depression in terminally ill cancer patients. This review describes in detail the synthesis, metabolism, pharmacology, adverse drug reactions, and importance of psilocybin to neuroscience in the past and present.
doi_str_mv 10.1021/acschemneuro.8b00186
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2062836850</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2062836850</sourcerecordid><originalsourceid>FETCH-LOGICAL-a348t-4a653dc7704ff301314e8de4744f45338a4b1b9a2b545e1efd2993644c99fa6a3</originalsourceid><addsrcrecordid>eNp9kEtPwzAQhC0EoqXwDxDKkUuKHW8cm1uV8hIVIARny3E2wlUeJW4O_fe4akE9cdo9fDM7O4RcMjplNGE3xnr7hU2LQ99NZUEpk-KIjJkCGWdM8eODfUTOvF9SKhSV4pSMEqVSoVg2Jsl89v4c5bXx3lkfuTbKg6mzpo5ets7eOmwt3kZv3tWd3RSuPScnlak9XuznhHze333kj_Hi9eEpny1iw0GuYzAi5aXNMgpVxSnjDFCWCBlABSnn0kDBCmWSIoUUGVZlSMUFgFWqMsLwCbne-a767ntAv9aN8xbr2rTYDV4nVCSSC5nSgMIOtSGx77HSq941pt9oRvW2LX3Ylt63FWRX-wtD0WD5J_qtJwB0BwS5XnZD34aH__f8AeQueE4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2062836850</pqid></control><display><type>article</type><title>DARK Classics in Chemical Neuroscience: Psilocybin</title><source>ACS Publications</source><creator>Geiger, Haden A ; Wurst, Madeline G ; Daniels, R. Nathan</creator><creatorcontrib>Geiger, Haden A ; Wurst, Madeline G ; Daniels, R. Nathan</creatorcontrib><description>Psilocybin is found in a family of mushrooms commonly known as “magic mushrooms” that have been used throughout history to induce hallucinations. In the late 1950s Albert Hofmann, of Sandoz Laboratories, identified and synthesized the psychoactive compounds psilocybin and psilocin which are found in psilocybe mushrooms. Psilocybin was marketed by Sandoz as Indocybin for basic psychopharmacological and therapeutic clinical research. Psilocybin saw a rapid rise in popularity during the 1960s and was classed as a Schedule I drug in 1970. This led to a significant decrease in psilocybin research. Recently, however, preliminary studies with psilocybin have shown promise as potential for the treatment of obsessive compulsive disorder, alcohol addiction, tobacco addiction, and major depressive disorder, and the treatment of depression in terminally ill cancer patients. This review describes in detail the synthesis, metabolism, pharmacology, adverse drug reactions, and importance of psilocybin to neuroscience in the past and present.</description><identifier>ISSN: 1948-7193</identifier><identifier>EISSN: 1948-7193</identifier><identifier>DOI: 10.1021/acschemneuro.8b00186</identifier><identifier>PMID: 29956917</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><ispartof>ACS chemical neuroscience, 2018-10, Vol.9 (10), p.2438-2447</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a348t-4a653dc7704ff301314e8de4744f45338a4b1b9a2b545e1efd2993644c99fa6a3</citedby><cites>FETCH-LOGICAL-a348t-4a653dc7704ff301314e8de4744f45338a4b1b9a2b545e1efd2993644c99fa6a3</cites><orcidid>0000-0001-8482-8208</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/acschemneuro.8b00186$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/acschemneuro.8b00186$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>314,776,780,2752,27053,27901,27902,56713,56763</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29956917$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Geiger, Haden A</creatorcontrib><creatorcontrib>Wurst, Madeline G</creatorcontrib><creatorcontrib>Daniels, R. Nathan</creatorcontrib><title>DARK Classics in Chemical Neuroscience: Psilocybin</title><title>ACS chemical neuroscience</title><addtitle>ACS Chem. Neurosci</addtitle><description>Psilocybin is found in a family of mushrooms commonly known as “magic mushrooms” that have been used throughout history to induce hallucinations. In the late 1950s Albert Hofmann, of Sandoz Laboratories, identified and synthesized the psychoactive compounds psilocybin and psilocin which are found in psilocybe mushrooms. Psilocybin was marketed by Sandoz as Indocybin for basic psychopharmacological and therapeutic clinical research. Psilocybin saw a rapid rise in popularity during the 1960s and was classed as a Schedule I drug in 1970. This led to a significant decrease in psilocybin research. Recently, however, preliminary studies with psilocybin have shown promise as potential for the treatment of obsessive compulsive disorder, alcohol addiction, tobacco addiction, and major depressive disorder, and the treatment of depression in terminally ill cancer patients. This review describes in detail the synthesis, metabolism, pharmacology, adverse drug reactions, and importance of psilocybin to neuroscience in the past and present.</description><issn>1948-7193</issn><issn>1948-7193</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kEtPwzAQhC0EoqXwDxDKkUuKHW8cm1uV8hIVIARny3E2wlUeJW4O_fe4akE9cdo9fDM7O4RcMjplNGE3xnr7hU2LQ99NZUEpk-KIjJkCGWdM8eODfUTOvF9SKhSV4pSMEqVSoVg2Jsl89v4c5bXx3lkfuTbKg6mzpo5ets7eOmwt3kZv3tWd3RSuPScnlak9XuznhHze333kj_Hi9eEpny1iw0GuYzAi5aXNMgpVxSnjDFCWCBlABSnn0kDBCmWSIoUUGVZlSMUFgFWqMsLwCbne-a767ntAv9aN8xbr2rTYDV4nVCSSC5nSgMIOtSGx77HSq941pt9oRvW2LX3Ylt63FWRX-wtD0WD5J_qtJwB0BwS5XnZD34aH__f8AeQueE4</recordid><startdate>20181017</startdate><enddate>20181017</enddate><creator>Geiger, Haden A</creator><creator>Wurst, Madeline G</creator><creator>Daniels, R. Nathan</creator><general>American Chemical Society</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8482-8208</orcidid></search><sort><creationdate>20181017</creationdate><title>DARK Classics in Chemical Neuroscience: Psilocybin</title><author>Geiger, Haden A ; Wurst, Madeline G ; Daniels, R. Nathan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a348t-4a653dc7704ff301314e8de4744f45338a4b1b9a2b545e1efd2993644c99fa6a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Geiger, Haden A</creatorcontrib><creatorcontrib>Wurst, Madeline G</creatorcontrib><creatorcontrib>Daniels, R. Nathan</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>ACS chemical neuroscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Geiger, Haden A</au><au>Wurst, Madeline G</au><au>Daniels, R. Nathan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>DARK Classics in Chemical Neuroscience: Psilocybin</atitle><jtitle>ACS chemical neuroscience</jtitle><addtitle>ACS Chem. Neurosci</addtitle><date>2018-10-17</date><risdate>2018</risdate><volume>9</volume><issue>10</issue><spage>2438</spage><epage>2447</epage><pages>2438-2447</pages><issn>1948-7193</issn><eissn>1948-7193</eissn><abstract>Psilocybin is found in a family of mushrooms commonly known as “magic mushrooms” that have been used throughout history to induce hallucinations. In the late 1950s Albert Hofmann, of Sandoz Laboratories, identified and synthesized the psychoactive compounds psilocybin and psilocin which are found in psilocybe mushrooms. Psilocybin was marketed by Sandoz as Indocybin for basic psychopharmacological and therapeutic clinical research. Psilocybin saw a rapid rise in popularity during the 1960s and was classed as a Schedule I drug in 1970. This led to a significant decrease in psilocybin research. Recently, however, preliminary studies with psilocybin have shown promise as potential for the treatment of obsessive compulsive disorder, alcohol addiction, tobacco addiction, and major depressive disorder, and the treatment of depression in terminally ill cancer patients. This review describes in detail the synthesis, metabolism, pharmacology, adverse drug reactions, and importance of psilocybin to neuroscience in the past and present.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>29956917</pmid><doi>10.1021/acschemneuro.8b00186</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-8482-8208</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1948-7193
ispartof ACS chemical neuroscience, 2018-10, Vol.9 (10), p.2438-2447
issn 1948-7193
1948-7193
language eng
recordid cdi_proquest_miscellaneous_2062836850
source ACS Publications
title DARK Classics in Chemical Neuroscience: Psilocybin
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T12%3A53%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=DARK%20Classics%20in%20Chemical%20Neuroscience:%20Psilocybin&rft.jtitle=ACS%20chemical%20neuroscience&rft.au=Geiger,%20Haden%20A&rft.date=2018-10-17&rft.volume=9&rft.issue=10&rft.spage=2438&rft.epage=2447&rft.pages=2438-2447&rft.issn=1948-7193&rft.eissn=1948-7193&rft_id=info:doi/10.1021/acschemneuro.8b00186&rft_dat=%3Cproquest_cross%3E2062836850%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2062836850&rft_id=info:pmid/29956917&rfr_iscdi=true